Assenagon Asset Management S.A. Boosts Stock Holdings in Integra LifeSciences Holdings Corporation $IART

Assenagon Asset Management S.A. increased its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 15.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 526,302 shares of the life sciences company’s stock after buying an additional 71,950 shares during the period. Assenagon Asset Management S.A. owned 0.68% of Integra LifeSciences worth $6,537,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IART. GAMMA Investing LLC raised its position in shares of Integra LifeSciences by 55.3% in the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 913 shares during the period. Osaic Holdings Inc. boosted its stake in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 1,104 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Integra LifeSciences by 595.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after acquiring an additional 6,814 shares during the period. Amundi increased its stake in shares of Integra LifeSciences by 17,193.8% in the 2nd quarter. Amundi now owns 11,068 shares of the life sciences company’s stock valued at $150,000 after purchasing an additional 11,004 shares in the last quarter. Finally, Inceptionr LLC purchased a new position in shares of Integra LifeSciences in the 3rd quarter valued at about $164,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Shares of NASDAQ IART opened at $9.20 on Friday. The firm has a 50-day simple moving average of $10.67 and a 200-day simple moving average of $12.45. The stock has a market capitalization of $717.05 million, a price-to-earnings ratio of -1.37 and a beta of 1.02. The company has a quick ratio of 1.46, a current ratio of 2.54 and a debt-to-equity ratio of 1.66. Integra LifeSciences Holdings Corporation has a 52 week low of $8.70 and a 52 week high of $22.27.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.04. The firm had revenue of $434.93 million for the quarter, compared to analyst estimates of $429.62 million. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. Integra LifeSciences’s quarterly revenue was down 1.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.97 earnings per share. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. On average, equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IART has been the topic of a number of recent analyst reports. Citigroup decreased their target price on Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a research report on Wednesday, March 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Wells Fargo & Company upgraded shares of Integra LifeSciences to a “hold” rating in a research report on Wednesday, March 18th. Finally, Wall Street Zen lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Integra LifeSciences currently has an average rating of “Reduce” and an average target price of $14.40.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.